lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia

Chen, Cunte; Wang, Peipei; Mo, Wenjian; Zhang, Yuping; Wei, Zhou; Deng, Tingfen; Zhou, Ming; Chen, Xiaowei; Wang, Shunqing; Wang, Caixia

doi:10.3892/ol.2019.10591

Cited by 16 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, researchers found that lncRNA CCDC26 level in patients with AML was significantly associated with age, anemia, risk stratification, and remission. Furthermore, the overall survival of AML patients with a high expression level of lncRNA CCDC26 was poor ( P = 0.0105) 12 .…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis

Shi

et al. 2021

Cell Transplant

View full text Add to dashboard Cite

LncRNA CCDC26 is aberrantly expressed in myeloid leukemia (ML) and promotes myeloid leukemia progression, but the potential mechanism of CCDC26 in regulating ML progression is unclear. In this study, we observed that lncRNA CCDC26 was upregulated in both chronic and acute ML cell lines. LncRNA CCDC26 promoted the proliferation and invasion of K562 and HL-60 cells, which was determined by cell counting kit-8 test and Transwell invasion assay. Flow cytometry showed that lncRNA CCDC26 inhibited cell apoptosis. Bioinformatics and expression correlation analyses revealed that there was a potential interaction between CCDC26 and CUGBP Elav-like family member 2 (CELF2) protein, an RNA bind protein (RBP). Then the relationship between CCDC26 and the RBP CELF2 was identified by using RNA pull-down and RNA immunoprecipitation (RNA-IP) assays. Further analysis showed that overexpression of CCDC26 could noticeably upregulate circRNA_ANKIB1 expression via sponging CELF2. Subsequently, we found that overexpressed circRNA_ANKIB1 could significantly promote proline rich 11 (PRR11) protein expression by sponging miR-195a-5p. Moreover, PRR11 was also upregulated by CCDC26 and downregulated by CELF2. Mechanically, we uncovered that the miR-195a-5p inhibitor activated the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways through upregulating PRR11 protein expression. Furthermore, the inhibitors of AKT, p65-NF-κB, or Bcl-2 could inhibit the effect of the miR-195a-5p inhibitor on ML cell behaviors. In conclusion, lncRNA CCDC26 could upregulate PRR11 protein expression by sponging miR-195a-5p, thereby activating the PI3K/AKT and NF-κB pathways to enhance ML cell proliferation and invasion and suppress cell apoptosis.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis

Shi

et al. 2021

Cell Transplant

View full text Add to dashboard Cite

show abstract

“…Numerous lncRNAs are deregulated in different sorts of malignant growths, including head and neck cancer [92]. Unmistakable expression profiles of lncRNA have been distinguished in leukemia [9,33,35,45,[47][48][49][93][94][95][96][97][98][99]. Some of these have been demonstrated to have wellunderstood jobs in the development and progression of leukemia, suggesting the vital use of lncRNAs as novel biomarkers and potential targets for the treatment of leukemia.…”

Section: Long Non-coding Rnasmentioning

confidence: 99%

Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance

et al. 2020

View full text Add to dashboard Cite

Early-stage detection of leukemia is a critical determinant for successful treatment of the disease and can increase the survival rate of leukemia patients. The factors limiting the current screening approaches to leukemia include low sensitivity and specificity, high costs, and a low participation rate. An approach based on novel and innovative biomarkers with high accuracy from peripheral blood offers a comfortable and appealing alternative to patients, potentially leading to a higher participation rate. Recently, non-coding RNAs due to their involvement in vital oncogenic processes such as differentiation, proliferation, migration, angiogenesis and apoptosis have attracted much attention as potential diagnostic and prognostic biomarkers in leukemia. Emerging lines of evidence have shown that the mutational spectrum and dysregulated expression of non-coding RNA genes are closely associated with the development and progression of various cancers, including leukemia. In this review, we highlight the expression and functional roles of different types of non-coding RNAs in leukemia and discuss their potential clinical applications as diagnostic or prognostic biomarkers and therapeutic targets.

show abstract

“…A total of 7444 lncRNAs (3606 known and 3838 novel lncRNAs) were identified as eRNAs by comparing the genomic coordinates of lncRNAs overlapped with the known enhancer regions from Ensembl and VISTA enhancer databases. For example, lncRNA CCDC26 was found to be a novel biomarker in acute myeloid leukemia and also found to control myeloid leukemia cell growth ( 50 , 51 ). Using our in silico analysis method, we discerned that CCDC26 is nearby (enhancer of the gene) the hs1709 (VISTA ID) enhancer region.…”

Section: Resultsmentioning

confidence: 99%

OUP accepted manuscript

et al. 2021

View full text Add to dashboard Cite

Over the past few years, with the rapid growth of deep-sequencing technology and the development of computational prediction algorithms, a large number of long non-coding RNAs (lncRNAs) have been identified in various types of human cancers. Therefore, it has become critical to determine how to properly annotate the potential function of lncRNAs from RNA-sequencing (RNA-seq) data and arrange the robust information and analysis into a useful system readily accessible by biological and clinical researchers. In order to produce a collective interpretation of lncRNA functions, it is necessary to integrate different types of data regarding the important functional diversity and regulatory role of these lncRNAs. In this study, we utilized transcriptomic sequencing data to systematically observe and identify lncRNAs and their potential functions from 5034 The Cancer Genome Atlas RNA-seq datasets covering 24 cancers. Then, we constructed the ‘lncExplore’ database that was developed to comprehensively integrate various types of genomic annotation data for collective interpretation. The distinctive features in our lncExplore database include (i) novel lncRNAs verified by both coding potential and translation efficiency score, (ii) pan-cancer analysis for studying the significantly aberrant expression across 24 human cancers, (iii) genomic annotation of lncRNAs, such as cis -regulatory information and gene ontology, (iv) observation of the regulatory roles as enhancer RNAs and competing endogenous RNAs and (v) the findings of the potential lncRNA biomarkers for the user-interested cancers by integrating clinical information and disease specificity score. The lncExplore database is to our knowledge the first public lncRNA annotation database providing cancer-specific lncRNA expression profiles for not only known but also novel lncRNAs, enhancer RNAs annotation and clinical analysis based on pan-cancer analysis. lncExplore provides a more complete pathway to highly efficient, novel and more comprehensive translation of laboratory discoveries into the clinical context and will assist in reinterpreting the biological regulatory function of lncRNAs in cancer research. Database URL http://lncexplore.bmi.nycu.edu.tw

show abstract

lncRNA‑CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia

Cited by 16 publications

References 42 publications

RETRACTED: LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis

RETRACTED: LncRNA CCDC26 Interacts with CELF2 Protein to Enhance Myeloid Leukemia Cell Proliferation and Invasion via the circRNA_ANKIB1/miR-195-5p/PRR11 Axis

Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance

OUP accepted manuscript

Contact Info

Product

Resources

About